Matrix metalloproteinase-9 activity in the cerebrospinal fluid and serum of dogs with acute spinal cord trauma from intervertebral disk disease

American Journal of Veterinary Research

Volumn 67, Issue 2, 2006, Pages 283-287

  Levine, Jonathan M ^a   Ruaux, Craig G ^a   Bergman, Robert L ^a,c   Coates, Joan R ^b   Steiner, Jörg M ^a   Williams, David A ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c Carolina Veterinary Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GELATINASE B; METHYLPREDNISOLONE; PREDNISONE;

ACUTE DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOG DISEASE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HOSPITALIZATION; INTERVERTEBRAL DISK DISEASE; LAMINECTOMY; MALE; NONHUMAN; PARAPLEGIA; PATHOPHYSIOLOGY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; SPINAL CORD INJURY; ZYMOGRAPHY;

ANIMALS; DOG DISEASES; DOGS; FEMALE; INTERVERTEBRAL DISK DISPLACEMENT; MALE; MATRIX METALLOPROTEINASE 9; SPINAL CORD INJURIES;

ANIMALIA; CANIS FAMILIARIS; RODENTIA;

EID: 33344470254     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.2.283     Document Type: Article

References (26)

1. Dumont RJ, Okonkwo DO, Verma S, et al. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 2001;24:254-264.
2. Choi DW. Excitotoxic cell death. J Neurobiol 1992;23:1261-1276.
3. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol 1998;2:466-471.
4. Chandler S, Coates R, Gearing A, et al. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995;201:223-226.
5. Chandler S, Miller KM, Clements JM, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 1997;72:155-161.
6. Duffy MJ, McCarthy K. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Int J Oncol 1998;12:1343-1348.
7. Lee MA, Palace J, Stabler G, et al. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999;122:191-197.
8. Noble LJ, Donovan F, Igarashi T, et al. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 2002;22:7526-7535.
9. Steder-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996;7:147-154.
10. Matsui Y, Maeda M, Nakagami W, et al. The involvement of matrix metalloproteinases and inflammation in lumbar disk herniation. Spine 1998;23:863-869.
11. de Castro RC, Burns CL, McAdoo DJ, et al. Metalloproteinase increases in the injured rat spinal cord. Neuroreport 2000;11:3551-3554.
12. Duchossoy YS, Arnaud S, Feldblum S. Matrix metalloproteinases: potential therapeutic target in spinal cord injury. Clin Chem Lab Med 2001;39:362-367.
13. Goussev S, Hsu JY, Lin Y, et al. Differential temporal expression of matrix metalloproteinases after spinal cord injury: relationship to revascularization and wound healing. J Neurosurg 2003;99(suppl 2):188-197.
14. Olby N. Current concepts in the management of acute spinal cord injury. J Vet Intern Med 1999;13:399-407.
15. Hoerlein BF. Intervertebral disk disease. In: Oliver JE, Hoerlein BF, Mayhew IG, eds. Veterinary neurology. Philadelphia: WB Saunders Co, 1987;321-341.
16. Hoerlein BF. Intervertebral disk disease. In: Hoerlein BF, ed. Canine neurology: diagnosis and treatment. Philadelphia: WB Saunders Co, 1978;470-560.
17. Gage ED. Incidence of clinical intervertebral disk disease in the dog. J Am Anim Hosp Assoc 1975;11:135-138.
18. Goggin JE, Li A, Franti CE. Canine intervertebral disk disease: characterization by age, sex, breed, and anatomic site of involvement. Am J Vet Res 1970;31:1687-1692.
19. Borenstein D. Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. 1996;8:124-129.
20. Olby N, Levine J, Harris T, et al. Long-term functional outcome of dogs with severe injuries of the thoracolumbar spinal cord: 87 cases (1996-2001). J Am Vet Med Assoc 2003;222:762-769.
21. Davies JV, Sharp NJ. A comparison of conservative treatment and fenestration for thoracolumbar intervertebral disk disease in the dog. J Small Anim Pract 1983;24:721-729.
22. Denny HR. The lateral fenestration of canine thoracolumbar disk protrusions: a review of 30 cases. J Small Anim Pract 1978;19:259-266.
23. Bergman RL, Inzana KD, Inzana TJ. Characterization of matrix metalloproteinase-2 and -9 in cerebrospinal fluid of clinically normal dogs. Am J Vet Res 2002;63:1359-1362.
24. Takeshita S, Tokutomi T, Kawase H, et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 2001;125:340-344.
25. Yokota H, Kumata T, Taketaba T, et al. High expression of 92 kDa type IV collagenase (matrix metalloproteinase-9) in canine mammary adenocarcinoma. Biochim Biophys Acta 2001;1568:7-12.
26. Rosenberg GA, Dencoff JE, Correa N Jr, et al. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996; 46:1626-1632.